Category: BÜHLMANN Quantum Blue® Infliximab

New Health Canada Licences: Quantum Blue® Infliximab Assay, IBDoc®,CALEX® Cap

BUHLMANN Diagnostics Corp (BDC), BÜHLMANN Laboratories AG’s North American affiliate is proud to announce that three of its novel products, Quantum Blue® Infliximab Assay, IBDoc® and CALEX®Cap have received Medical Device Licences from Health Canada and are now commercially available in Canada. Quantum Blue® Infliximab® and CALEX® CAP devices were approved as Class II medical
Continue Reading

Quantum Blue® Infliximab Assay Highlights

US: BÜHLMANN Quantum Blue® Infliximab is for Research Use Only in the US. Not to be used in diagnostic procedures. Canada: BÜHLMANN Quantum Blue® Infliximab: Health Canada License: 98838 Simple, Fast, Accurate Quantitative Results BÜHLMANN’s Quantum Blue® Product line is designed with an innovative solution based on established lateral flow technology which utilizes highly specific monoclonal antibodies to capture
Continue Reading

Integration of Controls into BUHMANN Quantum Blue® Assays

Quantum Blue® Lateral Flow Assays: Simple, Fast, Accurate Quantitative Results Now Even More Convenient with 2 Lot Specific Ready-to-use Controls! Available NOW with Integrated Controls: Quantum Blue® Infliximab Assay The BÜHLMANN Quantum Blue® Infliximab is the ONLY  quantitative rapid test in the market for infliximab that can provide fast, reliable information for infliximab.  The test is designed for the selective
Continue Reading
Sign Up for BUHLMANN Updates!

Enter your email and stay on top of things,